[go: up one dir, main page]

AU2001248197A1 - Novel amino carboxy alkyl derivatives of barbituric acid - Google Patents

Novel amino carboxy alkyl derivatives of barbituric acid

Info

Publication number
AU2001248197A1
AU2001248197A1 AU2001248197A AU4819701A AU2001248197A1 AU 2001248197 A1 AU2001248197 A1 AU 2001248197A1 AU 2001248197 A AU2001248197 A AU 2001248197A AU 4819701 A AU4819701 A AU 4819701A AU 2001248197 A1 AU2001248197 A1 AU 2001248197A1
Authority
AU
Australia
Prior art keywords
group
compound
formula
cooh
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001248197A
Other languages
English (en)
Inventor
Kenneth Curry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2001248197A1 publication Critical patent/AU2001248197A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/66—Thiobarbituric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001248197A 2000-04-18 2001-04-18 Novel amino carboxy alkyl derivatives of barbituric acid Abandoned AU2001248197A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA002306170A CA2306170A1 (fr) 2000-04-18 2000-04-18 Nouveaux derives amines et carboxyles de l'acide barbiturique
CA2306170 2000-04-18
PCT/CA2001/000503 WO2001079185A1 (fr) 2000-04-18 2001-04-18 Nouveaux derives amino carboxy alkyle d'acide barbiturique

Publications (1)

Publication Number Publication Date
AU2001248197A1 true AU2001248197A1 (en) 2001-10-30

Family

ID=4165956

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001248197A Abandoned AU2001248197A1 (en) 2000-04-18 2001-04-18 Novel amino carboxy alkyl derivatives of barbituric acid

Country Status (7)

Country Link
US (1) US20030199533A1 (fr)
EP (1) EP1276727A1 (fr)
AU (1) AU2001248197A1 (fr)
CA (1) CA2306170A1 (fr)
MX (1) MXPA02010405A (fr)
NZ (1) NZ522195A (fr)
WO (1) WO2001079185A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093820A (en) 1997-10-02 2000-07-25 Taro Pharmaceutical Industries Ltd. Method and reagents for N-alkylating ureides
US7683071B2 (en) 2000-07-26 2010-03-23 Taro Pharmaceuticals Industries Ltd. Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
US6756379B2 (en) 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
US6939873B2 (en) 2000-07-26 2005-09-06 Taro Pharmaceuticals Industries Limited Non-sedating barbituric acid derivatives
WO2003063872A1 (fr) * 2002-01-30 2003-08-07 Taro Pharmaceutical Industries Ltd. Derives d'acide barbiturique non sedatifs
WO2004052350A2 (fr) 2002-12-11 2004-06-24 Taro Pharmaceutical Industries Limited Methode de traitement de troubles moteurs a l'aide de derives de l'acide barbiturique
AU2004315771A1 (en) * 2003-12-04 2005-08-25 3M Innovative Properties Company Sulfone substituted imidazo ring ethers
AU2006282896A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258357A3 (fr) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenèse avec inhibiteur de l'acetylcholinestérase
WO2007047978A2 (fr) 2005-10-21 2007-04-26 Braincells, Inc. Modulation de la neurogenese par inhibition de la pde
JP2009513672A (ja) 2005-10-31 2009-04-02 ブレインセルス，インコーポレイティド 神経発生のｇａｂａ受容体媒介調節
KR101027480B1 (ko) * 2006-01-04 2011-04-06 삼성전자주식회사 통신 시스템에서 데이터 송수신 방법 및 시스템
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
EP2377531A2 (fr) 2006-05-09 2011-10-19 Braincells, Inc. Neurogénèse par modulation de l'angiotensine
US7998971B2 (en) 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (fr) 2009-02-25 2010-09-02 Braincells, Inc. Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
US12486254B2 (en) 2022-02-25 2025-12-02 Southern Research Institute Uracil derivatives for stimulating read-through of premature termination codons

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS176667B1 (fr) * 1975-02-17 1977-06-30
IL69722A (en) * 1983-09-14 1986-09-30 Taro Pharma Ind Oxopyrimidine derivatives and pharmaceutical compositions containing them
US4714838A (en) * 1986-10-31 1987-12-22 Minnesota Mining And Manufacturing Company Second harmonic generation with N,N'-substituted barbituric acids
GB9325368D0 (en) * 1993-12-10 1994-02-16 Univ Bristol Organic compounds
US5959109A (en) * 1996-05-15 1999-09-28 Neurocrine Biosciences, Inc. Compounds and methods for increasing endogenous levels of corticotropin-releasing factor

Also Published As

Publication number Publication date
WO2001079185A1 (fr) 2001-10-25
MXPA02010405A (es) 2004-09-06
EP1276727A1 (fr) 2003-01-22
CA2306170A1 (fr) 2001-10-18
NZ522195A (en) 2004-12-24
US20030199533A1 (en) 2003-10-23

Similar Documents

Publication Publication Date Title
EP1280760B1 (fr) Nouveaux composes spiro[2.4]heptane amino carboxy et derives associes
US20030199533A1 (en) Novel amino carboxy alkyl derivatives of barbituric acid
US6784202B1 (en) Cubane derivatives as metabotropic glutamate receptor agonists or antagonists and process for their preparation
US5473077A (en) Pyrrolidinyl di-carboxylic acid derivatives as metabotropic glutamate receptor agonists
EP1210338A2 (fr) Derives de 1,4 benzodiazepine utiles dans le traitement de maladies liees au systeme nerveux central
US7034055B1 (en) 2-aminoindane analogs
US6699909B1 (en) Aminoindanes
US20060025471A1 (en) Xanthenyl cubane analogs with activity at the metabotropic glutamate receptors
CA2406396A1 (fr) Nouveaux derives amino carboxy alkyle d'acide barbiturique
CA2407777A1 (fr) Nouveaux composes spiro¬2.4|heptane amino carboxy et derives associes
CA2376470A1 (fr) Nouveaux amino-indanes
CA2376476A1 (fr) Analogues de 2-aminoindane
US5426114A (en) ω-[2-(tetrazolylalkyl)cyclohexyl]-2-aminoalkanoic acids as antagonists of excitatory amino acid receptors
MXPA00010171A (en) Cubane derivatives as metabotropic glutamate receptor antagonists and process for their preparation
CA2328984A1 (fr) Derives du cubane agissant comme antagonistes du recepteur du glutamate metabotropique, et procede de preparation desdits derives
EP0826663B1 (fr) Dérivés d'alkynylaminoacides et leur utilisation comme composés pharmaceutiques
CA2381260A1 (fr) Nouveaux composes de 1,4-benzodiazepine et derives de ces derniers